Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary ...

A positive trend in overall survival was observed, favoring sacituzumab govitecan over chemotherapy, though data is still ...

A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management. A panelist discusses how the therapeutic landscape of extensive-stage small cell lung cancer ...

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues ...

In an interview with Targeted Oncology at the 2025 North American Neuroendocrine Tumor Society (NANETS) Symposium, Michael ...

The DISCUS trial demonstrated improved QOL with 3 cycles of chemotherapy compared to 6 cycles in advanced urothelial cancer patients. Both treatment arms showed similar overall survival and ...

The segment concludes that long-term data reinforce the durability and clinical relevance of combination immunotherapy, ...

A panelist discusses how both lurbinectedin and tarlatamab remain important in the management of relapsed small cell lung ...

Park says patient-specific factors that influence his treatment selection include the presence of liver disease, ...

M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...

The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...

The FDA accepted the investigational new drug application for UGN-103 in April 2024. These new positive data position the ...